动脉僵硬度和骨保护素对稳定型冠状动脉疾病患者的预后评估(4)
[8]Nugroho J， Widorini W. Correlation between osteoprotegerin serum level and coronary calcification using coronary artery calcium score in patient with moderate-severe cardiovascular risk factor[J]. Int J Angiol，2017，26(4)：234-237.
[9]Members TF， Montalescot G， Sechtem U， et al. 2013 ESC guidelines on the management of stable coronary artery disease： the task force on the management of stable coronary artery disease of the european society of cardiology[J]. Eur Heart J，2013，34(38)：2949-3003.
[10]金晶，秦慧娟.益氣活血化痰方联合小剂量阿托伐他汀对高危性COPD患者动脉僵硬度、血液黏度及预后的影响研究[J].重庆医学，2017，46(28)：3943-3946.
[11]Rah S， Colquhoun DM， Marschner SL， et al. Persistent psychological distress and mortality in patients with stable coronary artery disease[J]. Heart，2017，103(23)：1860-1866.
[12]Ueland T， Akerblom A， Ghukasyan T， et al. Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes： insights from the PLATO (platelet inhibition and patient outcomes) trial[J]. J Am Heart Assoc，2018，7(2)：e007009.
[13]Grzelka A， Naskret D， Araszkiewicz A， et al. Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy： results from the poznań prospective study[J]. Adv Clin Exp Med，2017，26(9)：1343-1349.
[14]Ikonomidis I， Makavos G， Lekakis J. Arterial stiffness and coronary artery disease[J]. Curr Opin Cardiol，2015，30(4)：422-431.
[15]Siasos G， Oikonomou E， Maniatis K， et al. Prognostic significance of arterial stiffness and osteoprotegerin in patients with stable coronary artery disease[J]. Eur J Clin Invest，2018，48(3)：e12890., 百拇医药(延喜悦 黄永华)
[9]Members TF， Montalescot G， Sechtem U， et al. 2013 ESC guidelines on the management of stable coronary artery disease： the task force on the management of stable coronary artery disease of the european society of cardiology[J]. Eur Heart J，2013，34(38)：2949-3003.
[10]金晶，秦慧娟.益氣活血化痰方联合小剂量阿托伐他汀对高危性COPD患者动脉僵硬度、血液黏度及预后的影响研究[J].重庆医学，2017，46(28)：3943-3946.
[11]Rah S， Colquhoun DM， Marschner SL， et al. Persistent psychological distress and mortality in patients with stable coronary artery disease[J]. Heart，2017，103(23)：1860-1866.
[12]Ueland T， Akerblom A， Ghukasyan T， et al. Osteoprotegerin is associated with major bleeding but not with cardiovascular outcomes in patients with acute coronary syndromes： insights from the PLATO (platelet inhibition and patient outcomes) trial[J]. J Am Heart Assoc，2018，7(2)：e007009.
[13]Grzelka A， Naskret D， Araszkiewicz A， et al. Higher concentrations of osteoprotegerin in type 1 diabetic patients are related to retinopathy： results from the poznań prospective study[J]. Adv Clin Exp Med，2017，26(9)：1343-1349.
[14]Ikonomidis I， Makavos G， Lekakis J. Arterial stiffness and coronary artery disease[J]. Curr Opin Cardiol，2015，30(4)：422-431.
[15]Siasos G， Oikonomou E， Maniatis K， et al. Prognostic significance of arterial stiffness and osteoprotegerin in patients with stable coronary artery disease[J]. Eur J Clin Invest，2018，48(3)：e12890., 百拇医药(延喜悦 黄永华)